TERROSA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug TERROSA contains one active pharmaceutical ingredient (API):

1	Teriparatide UNII 10T9CSU89I - TERIPARATIDE
	Teriparatide (rhPTH(1-34)) is the active fragment (1-34) of endogenous human parathyroid hormone. Teriparatide is a bone formation agent to treat osteoporosis. The skeletal effects of teriparatide depend upon the pattern of systemic exposure.
	Read more about Teriparatide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TERROSA Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H05AA02	Teriparatide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues
Discover more medicines within H05AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1736096, 1736108
ES	Centro de información online de medicamentos de la AEMPS	1161159003
FR	Base de données publique des médicaments	68681263
GB	Medicines & Healthcare Products Regulatory Agency	378778, 378780, 378788
IE	Health Products Regulatory Authority	89066, 89067
IL	מִשְׂרַד הַבְּרִיאוּת	8546
IT	Agenzia del Farmaco	045257019, 045257021, 045257033, 045257045, 045257058
LT	Valstybinė vaistų kontrolės tarnyba	1081947, 1081948, 1088259
PL	Rejestru Produktów Leczniczych	100383995
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65771001, W65771002, W65771003